Chernobyl disaster anniversary puts spotlight on region's healthcare needs:
This article was originally published in Clinica
Amid a flurry of new data and recommended healthcare activities, today's 20th anniversary of the Chernobyl nuclear disaster of 1986 was marked by calls for an extensive, internationally-funded and independent programme of assessments of the health effects of the accident. The expectation is that such assessments might spur further measures to identify and act upon the affected region's healthcare service and investment needs.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.